Gastrointestinal tumors harbor T cells that recognize patients’ unique tumor antigens
CCR scientists, lead by Steven A. Rosenberg, M.D., Ph.D., have determined that many common gastrointestinal tumors bear mutations capable of eliciting an immune response, suggesting that immunotherapy could be an effective way to treat these common cancers. Read more...
Elaine Jaffe receives the 2019 USCAP Board’s Distinguished Pathologist award
Apr 11, 2019
Elaine Jaffe, M.D., Senior Investigator in the Laboratory of Pathology, has received the 2019 United States and Canadian Academy of Pathology (USCAP) Board’s Distinguished Pathologist award. The award recognizes an individual for making major contributions to pathology over the years. Read more...
New study delivers chemotherapy to the liver for metastatic colorectal cancer patients
Apr 3, 2019
In some patients, colorectal cancer spreads only to the liver. Patients with previously treated colorectal cancer that has spread only to the liver may be eligible to participate in a new clinical trial at the NIH Clinical Center. Read more...
CCR staff receive funding from the Department of Defense
Apr 2, 2019
Congratulations to the CCR staff who have received funding from the Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP). The CDMRP office manages medical research programs in breast, prostate and ovarian cancers, neurofibromatosis, military health and other specified areas. Read more...
Stephanie Goff featured in an episode of The Doctors
Apr 1, 2019
Stephanie Goff, M.D., Associate Research Physician in CCR’s Surgery Branch, was recently featured on The Doctors. In the clip, she discusses how harnessing the body’s own immune system and adoptive cell transfer (ACT) can treat certain types of cancer. Read more...
New clinical trial will determine if gliomas respond to immunotherapy
Apr 1, 2019
Gliomas make up about 80 percent of all malignant brain tumors. A new clinical trial at the Center for Cancer Research is investigating if the immunotherapy drug nivolumab is beneficial to patients with gliomas. Read more...
Harnessing T-cell “stemness” could enhance cancer immunotherapy
Mar 28, 2019
A new study led by Nicholas Restifo, M.D., Senior Investigator in CCR’s Surgery Branch, sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29, 2019, in Science, suggest a way to enhance the effectiveness of immunotherapies for cancer treatment. Read more...
Trial results show that younger lymphoma patients respond well to ibrutinib
Mar 26, 2019
A recent clinical trial using the drug ibrutinib reveals that patients under age 60 with diffuse large B-cell lymphoma are much more likely to tolerate the drug – and respond to it – compared to those age 60 and older. Read more...
Louis Staudt elected as a fellow of the AACR Academy
Mar 25, 2019
Louis Staudt, M.D., Ph.D., Co-Chief of the Lymphoid Malignancies Branch, was elected to the 2019 class of fellows of the American Association for Cancer Research (AACR) Academy. The mission of the AACR Academy is to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer, and to leverage the expertise of the global brain trust of fellows of the AACR Academy to advance the mission of the AACR to prevent and cure all cancers through research, education, communication and collaboration. Read more...
New clinical trial recruits the immune system to attack chronic lymphocytic leukemia
Mar 15, 2019
Chronic lymphocytic leukemia (CLL) is cancer that develops in blood-forming cells in the bone marrow. A new clinical trial is testing a way to boost the body’s natural immune cells and recruit them to attack and kill marked leukemia cells. Read more...
CCR researchers discover how protein translation disruptions can lead to cancer
Mar 11, 2019
A mutation in the gene U2AF1, which codes for a protein involved in cutting out key pieces of RNA, can also have widespread effects on the translation of messenger RNA into proteins. A close look at one affected protein, interleukin 8 (IL8), revealed increased production as a result of the mutation, leading to inflammation and cancer spread. Read more...